Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Autolus Therapeutics PLC Sponsored ADR (AUTL) vs Puma Biotechnology, Inc. (PBYI)

Autolus Therapeutics PLC Sponsored ADR and Puma Biotechnology, Inc. are both Biotechnology companies. Autolus Therapeutics PLC Sponsored ADR and Puma Biotechnology, Inc. are of similar size ($513.7M and $506.9M). Autolus Therapeutics PLC Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Puma Biotechnology, Inc. trades at 18.1×. Autolus Therapeutics PLC Sponsored ADR grew revenue faster over the last twelve months: 193.3% against −2.86%. Puma Biotechnology, Inc. has the higher net margin (11.6% vs −238.7%) and the higher return on invested capital (42.6% vs 0.00%). Across the 18 metrics below, Puma Biotechnology, Inc. leads on 15 and Autolus Therapeutics PLC Sponsored ADR on 3.

Valuation

Metric AUTL PBYI Biotechnology median
P/E n/m 18.11 7.88
P/S 4.22 2.15 11.47
P/B 6.61 3.60 2.52
Price to free cash flow n/m 17.43 21.16
EV/EBITDA n/m 10.42 0.74
EV/Sales 3.15 1.84 10.73
Earnings yield (56.99%) 5.52% (28.84%)
Free cash flow yield (51.29%) 5.74% (23.03%)

Profitability

Metric AUTL PBYI Biotechnology median
Gross margin 15.66% 74.83% 65.16%
Operating margin (210.78%) 13.16% 0.00%
Net margin (238.66%) 11.55% 0.00%
Free cash flow margin (198.26%) 17.79% 0.00%
Return on equity (133.00%) 21.97% (57.72%)
Return on assets (46.15%) 13.78% (49.22%)
Return on invested capital 0.00% 42.61% 0.00%

Growth

Metric AUTL PBYI Biotechnology median
Revenue growth (TTM) 193.29% (2.86%) 5.64%
EPS growth (last fiscal year) (25.58%) (1.61%) —
Revenue growth, 5-year CAGR 113.11% 0.29% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AUTL PBYI Biotechnology median
Debt to equity 1.04 0.00 0.00
Current ratio 4.89 2.91 4.73
Net debt to EBITDA 1.16 (1.60) 0.96

Dividend

Metric AUTL PBYI Biotechnology median
Dividend yield 22.22% — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric AUTL PBYI Biotechnology median
Market cap 513.69m 506.91m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack